NICE recommends Merck ’s erbitux to treat R/M SCCHN in oral cavity

The UK National Institute for Health and Care Excellence (NICE) has recommended the routine use of Merck ’s erbitux (cetuximab), in combination with platinum-based chemotherapy, to treat recurrent and / or metastatic (R/M) squamous cell carcinoma of t…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news